Achieve Life Sciences Inc (ACHV)
NASDAQ:ACHV
Want to see ACHV full AI Analyst Report?
ACHV Stock Chart & Stats
$5.10
-$0.11(-3.08%)
At close: 4:00 PM EST
$5.10
-$0.11(-3.08%)
Day’s Range― - ―
52-Week Range$2.00 - $6.03
Previous CloseN/A
Volume131.37K
Average Volume (3M)1.32M
Market Cap
$214.02M
Enterprise Value$204.86M
Total Cash (Recent Filing)$36.40M
Total Debt (Recent Filing)$14.96M
Price to Earnings (P/E)―
Beta2.59
Next Earnings
May 07, 2026EPS Estimate
-0.3Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)-0.28
Shares Outstanding53,239,986
10 Day Avg. Volume2,377,942
30 Day Avg. Volume1,320,294
Financial Highlights & Ratios
PEG Ratio-4.92
Price to Book (P/B)10.07
Price to Sales (P/S)0.00
P/FCF Ratio-4.38
Enterprise Value/Market Cap0.96
Enterprise Value/RevenueN/A
Enterprise Value/Gross Profit-898.49
Enterprise Value/Ebitda-3.80
Forecast
1Y Price Target
$13.20Price Target Upside158.82% Upside
Rating ConsensusStrong Buy
Number of Analyst Covering5
EPS Forecast (FY)-1.32
Revenue Forecast (FY)N/A
Bulls Say, Bears Say
Bulls Say
Clinical Efficacy And TolerabilityPhase 3 ORCA trials reported clear quit-rate improvements with cytisinicline and a favorable tolerability profile, supporting potential strong real-world adoption.
Competitive PositioningLimited direct-to-consumer marketing by a larger competitor preserves branded awareness space and could enable cytisinicline to capture market share if approved.
Label Expansion OpportunityA potential label expansion for e-cigarette cessation could create a distinct commercial segment and meaningfully enlarge the addressable market for cytisinicline.
Bears Say
Launch Timing And Financing RiskManufacturing-related regulatory delays may postpone the commercial launch and raise the company's near-term financing needs before product revenue begins.
Regulatory Inspection Classification RiskAn Official Action Indicated finding at a third-party manufacturing site increases the chance of a complete response letter and could force an NDA resubmission or significant remediation.
Third-party Manufacturing DependencyReliance on external manufacturers and limited visibility into remediation efforts creates uncertainty about supply readiness and commercial launch preparation.
Achieve Life Sciences News
ACHV FAQ
What was Achieve Life Sciences Inc’s price range in the past 12 months?
Achieve Life Sciences Inc lowest stock price was $2.00 and its highest was $6.03 in the past 12 months.
What is Achieve Life Sciences Inc’s market cap?
Achieve Life Sciences Inc’s market cap is $214.02M.
When is Achieve Life Sciences Inc’s upcoming earnings report date?
Achieve Life Sciences Inc’s upcoming earnings report date is May 07, 2026 which is in 9 days.
How were Achieve Life Sciences Inc’s earnings last quarter?
Achieve Life Sciences Inc released its earnings results on Mar 24, 2026. The company reported -$0.28 earnings per share for the quarter, beating the consensus estimate of -$0.288 by $0.008.
Is Achieve Life Sciences Inc overvalued?
According to Wall Street analysts Achieve Life Sciences Inc’s price is currently Undervalued.
Does Achieve Life Sciences Inc pay dividends?
Achieve Life Sciences Inc does not currently pay dividends.
What is Achieve Life Sciences Inc’s EPS estimate?
Achieve Life Sciences Inc’s EPS estimate is -0.3.
How many shares outstanding does Achieve Life Sciences Inc have?
Achieve Life Sciences Inc has 53,239,986 shares outstanding.
What happened to Achieve Life Sciences Inc’s price movement after its last earnings report?
Achieve Life Sciences Inc reported an EPS of -$0.28 in its last earnings report, beating expectations of -$0.288. Following the earnings report the stock price went down -28.395%.
Which hedge fund is a major shareholder of Achieve Life Sciences Inc?
Currently, no hedge funds are holding shares in ACHV
What is the TipRanks Smart Score and how is it calculated?
Smart Score combines eight research factors - such as analyst recommendations, hedge fund trends, and technical indicators - to measure a stock’s outlook. These signals are unified into a single score that reflects bullish or bearish momentum. See detailed methodology
Achieve Life Sciences Stock Smart Score
Outperform
1
2
3
4
5
6
7
8
9
10
Analyst Consensus
Strong Buy
Average Price Target:
$13.20 (158.82% Upside)
$13.20 (158.82% Upside)
Blogger Sentiment
Bullish
ACHV Sentiment 80%
Sector Average 72%
Sector Average 72%
Hedge Fund Trend
Increased
By 42.7K Shares
Last Quarter.
Last Quarter.
Crowd Wisdom
Very Negative
Last 7 Days ▼ 1.2%
Last 30 Days ▼ 2.3%
Last 30 Days ▼ 2.3%
Technicals
SMA
Negative
20 days / 200 days
Momentum
156.28%
12-Months-Change
Fundamentals
Return on Equity
-204.14%
Trailing 12-Months
Asset Growth
8.90%
Trailing 12-Months
Company Description
Achieve Life Sciences Inc
Achieve Life Sciences, Inc., a clinical-stage pharmaceutical company, develops and commercializes of cytisinicline for smoking cessation and nicotine addiction in Canada, the United States, and the United Kingdom. The company offers cytisinicline, a plant-based alkaloid that interacts with nicotine receptors in the brain that reduce the severity of nicotine withdrawal symptoms. It has license agreements with Sopharma AD and University of Bristol. The company is based in Vancouver, Canada.
ACHV Earnings Call
Q4 2026
0:00 / 0:00
Earnings Call Sentiment|Positive
The call conveyed meaningful progress on multiple strategic fronts: regulatory advancement (NDA acceptance and clear PDUFA date), an accelerated pathway for the vaping indication (CNPV), strong clinical and long-term tolerability data including peer-reviewed publication, commercial build-out using AI/digital capabilities, and steps to onshore manufacturing. Major risks highlighted include a limited cash balance relative to the current annualized burn (implying roughly an eight-month runway at current spend), GMP observations at a named manufacturer that introduce supply uncertainty, and the need for additional financing and payer access work ahead of a potential 1H 2027 launch. Overall, achievements and momentum around approval, clinical validation, and commercial preparation are substantial, but near-term financial and manufacturing risks are material and will require active management.View all ACHV earnings summariesACHV Stock 12 Month Forecast
Average Price Target
$13.20
▲(158.82% Upside)
Technical Analysis
Ownership Overview
1.68% Insiders
8.03% Mutual Funds
0.53% Other Institutional Investors
82.79% Public Companies and
Individual Investors